Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency.

Ross, C; Rangarajan, S; Karimi, M; Toogeh, G; Apte, S; Lissitchkov, T; Acharya, S; J Manco-Johnson, M; Srivastava, A; Brand, B; A Schwartz, B; Knaub, S; Peyvandi, F

doi:10.1111/jth.13923

Public

Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency.

Shared by NobleBlocks on Feb 1, 2018 • 12:00 AM UTC

Authors:

C Ross

S Rangarajan

M Karimi

Abstract

Essentials Congenital afibrinogenemia causes a potentially life-threatening bleeding and clotting tendency. Two human fibrinogen concentrates (HFCs) were compared in a randomized pharmacokinetic study. Bioequivalence was not shown for AUCnorm , which was significantly larger for the new HFC. Increas...

Subject

afibrinogenemia

comparative study

congenital

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!